Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Beta3 agonists reported by Dainippon

Aug. 16, 1996

GW-5823: CCK-A agonist for treatment of obesity

Aug. 16, 1996

ImmuCell, Agri-Mark establish lactoferrin JV

Aug. 16, 1996

Hypolipidemic agents described by Bayer

Aug. 16, 1996

RPR reports squalene synthase inhibitors

Aug. 16, 1996

Takeda claims benzothiepin derivatives to treat bone disease

Aug. 16, 1996

9-cis-retinoids as heart disease therapy described by American Cyanamid

Aug. 9, 1996

Columbia seeks FDA approval of Crinone

Aug. 9, 1996

Aldose reductase inhibitors disclosed by Nippon Zoki

Aug. 9, 1996

FDA approves phaseI/II trial of VivoRx's BetaRx-P

Aug. 9, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...